Insider Shareholders with Direct Ownership of Monopar Therapeutics (MNPR)
This section provides a comprehensive overview of the insiders with direct ownership of Monopar Therapeutics (MNPR). You can find detailed information about the size and nature of each insider's ownership stake, as well as the latest updates on their holdings.
Monopar Therapeutics Insider List
| Insider | Adquired | Disposed | Held | # of Trades | Last Transaction |
|---|---|---|---|---|---|
|
Michael J Brown
Director |
25,218 | 0 | 235,863 $3.45 Million | 14 |
Dec 31, 2023
Added 1.06%
|
| 0 | 125,000 | 166,667 $2.44 Million | 1 |
Feb 11, 2021
Reduced 6.68%
|
|
|
Kim R Tsuchimoto
Chief Financial Officer |
89,813 | 32,709 | 57,429 $840,186 | 34 |
Jun 30, 2024
Reduced 4.96%
|
|
Chandler Robinson
Chief Executive Officer |
334,049 | 79,152 | 56,162 $821,650 | 37 |
Sep 30, 2024
Reduced 3.3%
|
|
Andrew Cittadine
Chief Operating Officer |
216,315 | 21,994 | 39,869 $583,283 | 32 |
Sep 30, 2024
Reduced 1.32%
|
|
Arthur J Klausner
Director |
25,218 | 0 | 30,863 $451,525 | 14 |
Dec 31, 2023
Added 7.58%
|
|
Raymond Anderson
Director |
25,218 | 0 | 26,863 $393,005 | 14 |
Dec 31, 2023
Added 8.62%
|
|
Christopher M Starr
Director |
25,218 | 0 | 25,863 $378,375 | 14 |
Dec 31, 2023
Added 8.92%
|
|
Andrew Paul Mazar
Chief Scientific Officer |
11,904 | 3,782 | 22,124 $323,674 | 12 |
Mar 31, 2022
Reduced 2.08%
|
|
Karthik Radhakrishnan
Chief Financial Officer |
1,550 | 0 | 1,550 $22,676 | 1 |
Oct 28, 2024
Added 50.0%
|